iLite® anti-HER2 ADCC Activity Set

Add to my product list

This product contains a packaged set of the three individual products, one vial of each:
iLite® ADCC Effector (V) Assay Ready Cells (BM5001), 
iLite® ADCC Target HER2 (+) Assay Ready Cells (BM5011) 
iLite® ADCC Target HER2 (-) Assay Ready Cells (BM5016)
All three products are genetically engineered human cells to be used for measuring the ADCC activity of anti-HER2 antibodies. 

Product code
Detection system
Research Use Only (RUO)

The products included in the iLite® anti-HER2 ADCC Activity Set can be used for the quantification ADCC activity of anti-HER2 antibodies.

Application notes for the following assays are available:

  • Quantification of anti-HER2 ADCC activity (E-256-GB)

Antibody-dependent cell-mediated cytotoxicity (ADCC) is a mechanism whereby pathogenic cells are lysed by lymphocytes, most often Natural Killer (NK) cells. The mechanism involves binding of antibodies to surface antigens on the pathogen. Crosslinking of these antibodies to NK cells through the binding of the Fc-portion to Fc receptors on the NK cells leads to activation of the NK cell and formation of an immune synapse with the pathogenic cell. The NK cell releases cytotoxic granules containing granzymes and perforin into the synapse, leading to apoptosis of the targeted cell.

Breast cancer is the most common cancer in women worldwide, and the second most common cancer overall. Survival rates have improved in the recent years, and stratification of patients into subgroups has vastly improved treatment options for many patients. As an example, patients with HER2 positive breast cancer generally have a poor prognosis, but treatment with trastuzumab, a monoclonal antibody targeting the HER2 receptor, has shown to increase both overall survival and disease free survival when given together with chemotherapy. Trastuzumab’s mechanism of action is mediated in part by inducing ADCC when crosslinking HER2 positive cells with the patients immune cells. The drug was FDA approved for treatment of breast cancer patients in 1998, and many biosimilars are currently in development.

3 vials of iLite® Assay Ready Cells (>250 µL). For contents of the individual vials, please please consult the specific Product Specifications.